Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus in Advanced or Metastatic Breast Cancer
NCT00376688Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Clinical Benefit Rate at 24 months. Started Jul 2006; status: completed.
02
Drugs
temsirolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00376688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376688.